

ClinGen NTRK Fusions Somatic Cancer Variant Curation Expert Panel						
Start Date	Your Name	Do you work for a laboratory that offers fee-for-service testing related to the work of your Expert Panel?	Have you made substantial contributions to the literature implicating a gene:disease relationship that relates to the work of your Expert Panel?		Do you have any other existing or planned independent efforts that will potentially overlap with the scope of your ClinGen work? If so, please describe and also send an email describing the project(s) to the co-chairs and coordinator:	Please disclose any other relevant conflicts of interest (e.g. patents, intellectual property ownership, or paid consultancies related to any variants or genes associated with the work of your Expert Panel):
	Open-Ended Response	Response	Response	If yes, please list the genes:	Open-Ended Response	Open-Ended Response
3/18/20	Arpad Danos	No	No		No	None
3/9/20	Larissa Furtado	Yes	No		No	N.A
3/9/20	Angshumoy Roy	Yes	Yes	NTRK		
3/6/20	Alanna Church	Yes	Yes	NTRK1, NTRK2, NTRK3		Consultant for Bayer Oncology
1/29/20	Wan-Hsin Lin	No	No		No	I have nothing to disclose.
1/29/20	Gordana Raca	Yes	No		No independent activities in this area	Nothing to disclose
1/29/20	Alanna Church	Yes	Yes	NTRK1, NTRK2, NTRK3	Consultant for Bayer: NTRK Testing and Educational Gaps Advisory Board	
1/29/20	Jason Saiba	No	No		I am currently training to be a curator and ultimately an editor for the CIVIC knowledgebase.	I have nothing to disclose.
12/14/19	Larissa V. Furtado	No	No		No	N/A
12/11/19	Theodore Laetsch	No	Yes	NTRK fusions and TRK inhibitors	No	I have consulted for Bayer and Loxo Oncology related to NTRK fusions and for Novartis and Eli Lilly for unrelated matters.
12/10/19	Valentina Nardi	Yes	Yes	ETV6-NTRK3 (PMID 29099503 and one article just accepted by Blood Advances)	No	NONE